HEB On Other Exchanges

hemispherx biopharma inc (HEB) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

hemispherx biopharma inc (HEB) Related Bloomberg News

View More Bloomberg News

hemispherx biopharma inc (HEB) Related Businessweek News

No Related Businessweek News Found

hemispherx biopharma inc (HEB) Details

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company’s products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.

31 Employees
Last Reported Date: 04/1/19
Founded in 1990

hemispherx biopharma inc (HEB) Top Compensated Officers

Executive Vice Chairman, CEO & President
Total Annual Compensation: $835.3K
Chief Financial Officer
Total Annual Compensation: $292.0K
Executive Director of Governmental Relations,...
Total Annual Compensation: $387.7K
Compensation as of Fiscal Year 2018.
hemispherx biopharma inc
Hemispherx Announces Progress Toward Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center

Hemispherx Biopharma Inc. announced progress toward the opening of Roswell Park Comprehensive Cancer Center’s clinical study incorporating Ampligen as part of a treatment combination for prostate cancer. Roswell Park now has FDA authorization to proceed with its Phase 2 study investigating the effectiveness and safety of aspirin and Ampligen with or without interferon-alpha 2b (Intron A) compared to no drug treatments in a randomized three-arm study of patients with prostate cancer before undergoing radical prostatectomy. Ongoing clinical trials: Phase 1 /2 study of intraperitoneal chemo-immunotherapy in recurrent ovarian cancer at University of Pittsburgh Medical Center. Dr. R. Edwards, PI. Eleven of 12 planned patients enrolled in Stage I. Phase 2a study of Ampligen as component of chemokine modulatory regimen on colorectal cancer metastatic to liver at Roswell Park Comprehensive Cancer Center. Dr. P. Boland, PI. Six of 12 planned patients enrolled. Phase 2 study of metastatic triple-negative breast cancer using chemokine modulation therapy, including Ampligen and pembrolizumab at Roswell Park Comprehensive Cancer Center. Dr. M. Opyrchal, PI. Phase 2 study of advanced ovarian cancer using cisplatin, pembrolizumab, plus Ampligen at University of Pittsburgh Medical Center. Dr. R. Edwards, PI. Up to 45 patients to be enrolled. FDA-authorized Expanded Access Program (AMP-511) to treat ME/CFS patients.

Hemispherx Biopharma, Inc. Links Stanford’s ME/CFS Diagnostic to a Potential Path Forward for Ampligen Commercialization

Hemispherx Biopharma Inc. announced that the impressive results from a blood-based, real-time diagnostic test out of Stanford University demonstrates an ability to identify moderate to severe ME/CFS patients from normal controls. Currently ME/CFS is a disease of exclusion from other diseases, which manifest similar signs and symptoms with no specific ME/CFS laboratory diagnostic assay to aid the physician in a definitive diagnosis. While Hemispherx is currently focused on Ampligen in the treatment of cancer, for which there are multiple ongoing trials, regulatory approval of Ampligen in the treatment of ME/CFS in the United States is also a corporate goal. Profound fatigue is a universal symptom of severe ME/CFS and its quantitative documentation is a challenge. A functional ME/CFS diagnostic may remove this obstacle. Using blood samples from twenty patients with ME/CFS versus twenty normal controls, Stanford researchers were able to identify which samples came from people with ME/CFS by measuring the electrical impedance of the patient’s immune cells and plasma when osmotically stressed through exposure to high salt concentrations.

Hemispherx Biopharma, Inc. Announces Significant Progress in its Ampligen Recurrent Ovarian Cancer Program

Hemispherx Biopharma Inc. announced significant progress in its Ampligen recurrent ovarian cancer program at the University of Pittsburgh Medical Center (UPMC) under the leadership of the principal investigator, Robert Edwards, MD. The ovarian cancer program is being funded in part by an Ovarian Cancer Specialized Program of Research Excellence (SPORE) from the National Institutes of Health (NIH), which is supporting a Phase 1/2 study of intraperitoneal chemo-immunotherapy in recurrent ovarian cancer. Recently, an interim report was received by Hemispherx that summarizes results related to some of the laboratory objectives of this study which include characterization of the local immune responses during chemo-induced cell death as measured by serial assessment of peritoneal fluid cellular phenotypes and chemokine patterns. Currently, a second ovarian cancer clinical trial at UPMC is beginning to accrue patients. This is a Phase 2 investigator-sponsored trial fully funded by an industry grant that will evaluate Ampligen in combination with the checkpoint blockade drug, pembrolizumab. This much larger trial will test the combination of Ampligen and pembrolizumab in subjects with advanced recurrent ovarian carcinoma.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

HEB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HEB.
View Industry Companies

Industry Analysis


Industry Average

Valuation HEB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.9x
Price/Book 4.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact HEMISPHERX BIOPHARMA INC, please visit www.hemispherx.net. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.